Search results
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Morningstar· 1 day ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking ...
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress - Innate Pharma (NASDAQ:IPHA)
Benzinga· 24 hours agoTwo abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate's
Udenyca: Side effects and what to do about them
Medical News Today· 6 days agoUdenyca is a prescription drug used to help prevent infection with chemotherapy. Learn about the serious side effects it can cause and how to manage...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 2 days agoThe company has secured a composition of matter patent for Annamycin, ensuring market exclusivity...
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Digital Journal· 2 days agoThe trial is more than 50% enrolled and we are dosing cohort 5 The Company is on track to initiate part 1 of its upcoming dose optimization trial in 2Q 2024. The study will further evaluate ...
FY2026 EPS Estimates for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reduced by HC Wainwright
ETF DAILY NEWS· 2 days agoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) – Equities researchers at HC Wainwright cut their FY2026 EPS estimates for Rigel Pharmaceuticals in a research report issued on Wednesday ...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 2 days agoThe company has secured a composition of matter patent for Annamycin, ensuring market exclusivity...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day ago– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL
Aptose Reports Results for the First Quarter 2024
Digital Journal· 1 day agoTUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed ...
Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday
ETF DAILY NEWS· 4 days agoSyros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, May 14th. Analysts expect Syros Pharmaceuticals to post earnings ...